anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a pharmaceutical composition of palbociclib in the form of an amorphous solid dispersion for use in the treatment of breast cancer, such as metastatic breast cancer. The amorphous solid dispersion comprising: palbociclib or a pharmaceutically acceptable salt thereof; an acidic auxiliary material comprising more than one pharmaceutically acceptable acid, at least one of which is an organic acid; and a hydrophilic high molecular weight material. The acidic auxiliary material may comprise one or more pharmaceutically acceptable inorganic acids as well as the at least one organic acid. The pharmaceutically acceptable organic acid may be tartaric acid, fumaric acid, succinic acid, citric acid, lactic acid, malic acid, an aliphatic sulfonic acid, or an aromatic sulfonic acid. The aliphatic sulfonic acid may be methanesulfonic acid, ethanesulfonic acid, or isethionic acid. The aromatic sulfonic acid may be benzenesulfonic acid or p-toluenesulfonic acid. The pharmaceutically acceptable inorganic acid may be hydrochloric acid, sulfuric acid, or phosphoric acid. The hydrophilic high-molecular weight material may be povidone K30, copovidone VA64 (PVP VA64), Soluplus, hydroxypropylmethylcellulose E5, hydroxypropylmethylcellulose acetate succinate, hydroxypropyl-β-cyclodextrin, or sulfobutyl ether-β-cyclodextrin. The mass ratio of the high molecular weight material to palbociclib may be from 0.1:1 to 10:1 and the mass ration of the acidic auxiliary material to palbociclib may be from 0.2:1 to 5:1. The dissolution rate of the palbociclib or pharmaceutically acceptable salt thereof in a solution of pH 6.0 may be greater than 60 % over a time period of 60 minutes, or greater that 50 % over a time period of 5 minutes. The amorphous solid dispersion may be stable for at least one week when stored at a temperature of 40 °C and humidity of about 75 %.
The present invention discloses a method for monitoring an exercise. Acquire a relationship between a degree of active participation of an organism of a human body and an exercise intensity. Build up an energy metabolism system and build up a mathematical model describing that an energy expenditure depends on the exercise intensity and the degree of active participation of the organism of the human body for the energy metabolism system. Determine the degree of active participation of the organism based on the exercise intensity measured in the exercise by the relationship. Use the exercise intensity and the degree of active participation of the organism to estimate the energy expenditure by the mathematical model of the energy metabolism system. Monitor the exercise based on the energy expenditure.
Decades of neuroimaging studies have shown modest differences in brain structure and connectivity in depression, hindering mechanistic insights or the identification of risk factors for disease onset1. Furthermore, whereas depression is episodic, few longitudinal neuroimaging studies exist, limiting understanding of mechanisms that drive mood-state transitions. The emerging field of precision functional mapping has used densely sampled longitudinal neuroimaging data to show behaviourally meaningful differences in brain network topography and connectivity between and in healthy individuals2-4, but this approach has not been applied in depression. Here, using precision functional mapping and several samples of deeply sampled individuals, we found that the frontostriatal salience network is expanded nearly twofold in the cortex of most individuals with depression. This effect was replicable in several samples and caused primarily by network border shifts, with three distinct modes of encroachment occurring in different individuals. Salience network expansion was stable over time, unaffected by mood state and detectable in children before the onset of depression later in adolescence. Longitudinal analyses of individuals scanned up to 62 times over 1.5 years identified connectivity changes in frontostriatal circuits that tracked fluctuations in specific symptoms and predicted future anhedonia symptoms. Together, these findings identify a trait-like brain network topology that may confer risk for depression and mood-state-dependent connectivity changes in frontostriatal circuits that predict the emergence and remission of depressive symptoms over time.
Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) once daily for 8 weeks. Dose will be increased from milligram per day (3 mg/day) after 5 days based on Investigator's discretion, up to maximum of 12 mg/day.
PURPOSE:To obtain a protein synthesis inhibitor to be useful for an antiviral agent comprising an extract of a plant of the genus Acacia as an active ingredient. CONSTITUTION:This protein synthesis inhibitor comprises an extract of leaves, stems, barks, roots or seeds of a plant of the genus Acacia (e.g. Acacia melanoxylon) or a protein component contained in the extract as an active ingredient. The extract or the protein fraction has strong inhibitory activity against protein synthesis and shows antiviral activity against a great number of animal and plant viruses such as HIV, herpes virus or tobacco mosaic virus. Since the extract can be extracted from a plant of the genus Acacia occurring in a large amount in the world, the protein synthesis inhibitor can be extremely economically produced. The extract or a protein fraction is linked to an antigen by a well-known method, is provided with integrity with and permeability to bacteria or a specific cell such as cancer cell, inhibits its protein synthesis, can detory bacterial or the cancer cell and is usable as an antimicrobial agent or an anti-cancer agent.
Participants received intravenous infusions of Camrelizumab 200 mg in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) or Cisplatin 30 milligrams per square meter (mg/m\^2) followed by Irinotecan 65 mg/m\^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4/5/6). On Days 8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6), Cisplatin 30 mg/m\^2 and Irinotecan 65 mg/m\^2 was administered. Thereafter, participants received maintenance (Cycle onward) Camrelizumab 200 mg on Day 1 of every 21-day cycle with Apatinib 250mg until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
The present invention belongs to the technical field of polylactic acid materials and preparation methods therefor, and specifically relates to a piezoelectric polylactic acid material, and a preparation method and use therefor. Provided in the present invention is a piezoelectric polylactic acid material. The microstructure of the piezoelectric polylactic acid material is presented as follows: the material has a layered stacking structure, and a porous structure is formed between layers stacked with each other; and the piezoelectric constant of the obtained modified polylactic acid material is 5.2-35.3 pC/N, reaching a level equivalent to that of a traditional piezoelectric material. Therefore, the modified polylactic acid material has efficient dye/pigment degradation capability, that is, having huge application advantages in the fields of dye/pigment degradation and teeth whitening. In addition, also provided in the present invention is a preparation method for the piezoelectric polylactic acid composite material. The method is simple and efficient, and industrial production is easy to implement.
Non-Hodgkin's lymphoma (NHL) can be divided into two general prognostic groups: the indolent lymphomas and the aggressive lymphomas. Indolent lymphomas have a relatively good prognosis, with median survival time as long as 10 years, but they are not usually curable in advanced stages. Aggressive NHL constitutes about half of all cases of NHL in North America and Western Europe. Of the aggressive lymphomas, diffuse large B-cell lymphoma (DLBCL) is the most common type, accounting for up to 30 percent of newly diagnosed cases. The aggressive type of NHL has a shorter natural history; approximately 50-60% of these subjects can be cured with combination chemotherapy regimens. Even with recent advances, many patients with advanced stage DLBCL are not cured with conventional therapy. This leaves a subset of subjects who will eventually relapse or who are refractory to treatment.

Due to the variation in the clinical behavior of the different types of aggressive NHL, it is important to test lenalidomide in DLBCL. Other studies are addressing the activity of lenalidomide in the other types of aggressive lymphomas, as well as in indolent NHL. It is important to test lenalidomide in combination therapy. This study is focused on treating subjects with relapsed or refractory DLBCL using oral lenalidomide in combination with oral dexamethasone.
Patients with polycythemia defined as hematocrit level greater than or equal to 49% in men and 48% in women, whatever the suspected etiology. Primitive and secondary polycythemia are eligible in this observational study. Patients should not have start any cytoreductive therapy prior inclusion.
PURPOSE: A face-pack composition containing kiwifruit extracts is provided to improve skin-lifting, moisturizing effect, and use feeling. CONSTITUTION: A face-pack composition contains kiwifruit extracts as an active component. The content amount of the kiwifruit extracts is 3-10 weight% based on total weight of the face-pack composition. The kiwifruit extract is extract of the kiwifruit leaf, extracts of kiwifruit, or a mixture thereof. A manufacturing method of the kiwifruit extracts comprises the following steps: cutting the kiwifruit in a size smaller than 3cm and putting the kiwifruit extract into distilled water; extract boiling at 100 deg. Celsius for 30 minutes or at room temperature for 24 hours after adding 94% ethanol and 94% methanol to the kiwifruit; freeze-drying and pulverizing after concentrating the extracts by using a rotary vacuum evaporator.
BACKGROUND: The study aimed to investigate and systematically review the evidence relating to the effects of high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) on vascular function such as arterial diameter, arterial stiffness, pulse wave velocity, blood flow, etc. in individuals with overweight and obesity.
METHODS: The entire content of PubMed (MEDLINE), Scopus, SPORT Discus® (via EBSCO host), CINAHL, and Web of Science were searched. Only experimental research studies conducted in adult participants aged ≥18 years, published in English before January 2023 were included.
RESULTS: A total of 5397 studies were reviewed for the title and abstract with 11 studies being included for data extraction. The review resulted in a total of 346 individuals with overweight and obesity with body mass index (BMI) ranging between 25-36 kg/m2. HIIT and MICT intensities resulted in 85%-95% and 60%-70% maximal heart rate (MHR) respectively. Seven out of 11 studies showed some concerns about the overall risk of bias. Six of 11 studies reported improving vascular function following HIIT than MICT.
CONCLUSION: HIIT is a more effective and time-efficient exercise for enhancing vascular functions in individuals with overweight and obesity, leading to improvements in flow-mediated dilation by 3.9% and arterial diameter by 4.8%, compared to MICT.
In the vibration group, a vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz) was applied to the middle/side area through which the sural nerve passes immediately below the knee of the extremity from which heel blood was to be collected approximately 30 seconds prior to commencement of the heel lance procedure. The vibration was continued throughout the heel lance procedure unless there was redness, swelling, bruising or a change in the skin integrity in the area to which the vibration was applied, and the vibration was stopped once the procedure was over.
During the use of Bi-level, we will maintain the PEEP value at 5cmH2O and modify the pressure support (PS) ventilation values, establishing the following values: 5, 7 and 10 cmH2O of PS, with all outcomes also being evaluated at the same time. end of 5 minutes.
The invention discloses a Y-region beauty device which can easily improve female vagina or inflammation of the part by a user. The Y-region beauty treatment equipment comprises a cartridge mounting part, a fumigation cartridge and a heat generating part. A cartridge insertion portion is formed at one side surface of the cartridge mounting portion. The fumigation cartridge is inserted and mounted in the cartridge insertion part, and the fumigation generating substance exists in a solid or liquid state in the fumigation cartridge. The heat generating part is disposed adjacent to the cartridge mounting part and supplies heat to the fumigation cartridge, so that fumigation of the fumigation cartridge can be performed. Thus, the Y-site beauty apparatus discharges the fumigant to the vagina of the female, so that the user can easily and conveniently prevent inflammation of the vagina, skin sensitization, improve malodor, etc. just by placing the Y-site beauty apparatus in front of the user's vagina.
Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive Poly-ICLC (adjuvant) administered subcutaneously.
The severity of adverse effects to a corticorelin injection appear to be dose-dependent. Dosages above 1 mcg/kg are not recommended. While few adverse effects have been observed at the 1 mcg/kg or 100 mcg dose, higher doses have been associated with transient tachycardia, decreased blood pressure, loss of consciousness, and asystole (see ADVERSE REACTIONS). These symptoms can be substantially reduced by administering the drug as a 30-second intravenous infusion instead of a bolus injection. At a dose of 200 mcg corticorelin, 4 of 60 volunteers and patients with disturbances of the hypothalamic-pituitary-adrenal (HPA) axis were reported to have had decreased blood pressures. One patient had a severe hypotensive reaction with asystole. Three other patients had an "absence-like" loss of consciousness lasting approximately 5 minutes. In subsequent investigations by the same researchers over a 3-year period using 100 mcg of corticorelin, one patient in approximately 150 to 200 experienced a severe drop in blood pressure and loss of sinus rhythm after receiving 55 mcg of corticorelin, which may have been due to interaction with heparin (see PRECAUTIONS - Drug Interactions).
Participants will receive 80 milligram per meter square (mg/m\^2) as an intravenous (IV) infusion at Weeks 0, 4, and every 8 weeks thereafter up to Week 244, along with commercial methotrexate (MTX) weekly through Week 28 at the same Body Surface Area (BSA)-based dosage (10 to 30 mg/m\^2 per week for participants with BSA less than \[\<\] 1.67 meter square (m\^2), or minimum of 15 mg/week for participants with BSA greater than or equal to \[\>=\] 1.67 m\^2) as at the time of study entry. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m\^2 every 8 weeks after completion of the Week 252 assessments.
Keloid formation has been linked to abnormal fibroblast function, such as excessive proliferation and extracellular matrix (ECM) production. Serum deprivation protein response (SDPR) is a crucial regulator of cellular function under diverse pathological conditions, yet its role in keloid formation remains unknown. The current work investigated the function of SDPR in regulating the proliferation, motility, and ECM production of keloid fibroblasts (KFs), as well as to decipher the mechanisms involved. Analysis of RNA sequencing data from the GEO database demonstrated significant down-regulation of SDPR in KF compared to normal fibroblasts (NFs). This down-regulation was also observed in clinical keloid specimens and isolated KFs. Overexpression of SDPR suppressed the proliferation, motility, and ECM production of KFs, while depletion of SDPR exacerbated the enhancing impact of TGF-β1 on the proliferation, motility, and ECM production of NFs. Mechanistic studies revealed that SDPR overexpression repressed TGF-β/Smad signal cascade activation in KFs along with decreased levels of phosphorylated Samd2/3, while SDPR depletion exacerbated TGF-β/Smad activation in TGF-β1-stimulated NFs. SDPR overexpression also repressed ERK1/2 activation in KFs, while SDPR depletion exacerbated ERK1/2 activation in TGF-β1-stimulated NFs. Inhibition of ERK1/2 abolished SDPR-depletion-induced TGF-β1/Smad activation, cell proliferation, motility, and ECM production in NFs. In conclusion, SDPR represses the proliferation, motility, and ECM production in KFs by blocking the TGF-β1/Smad pathway in an ERK1/2-dependent manner. The findings highlight the role of SDPR in regulating abnormal behaviors of fibroblasts associated with keloid formation and suggest it as a potential target for anti-keloid therapy development.
Embodiments of methods, systems, and apparatuses for generating a composited multimedia-based report are described. In one embodiment, a method includes capturing a medical image configured to be displayed on a medical image display device. The present methods may be independent of the medical image display, and may be able to capture images from any proprietary medical image viewer. The method may also include capturing description data related to the medical image. Additionally, the method may include processing the medical image and the description data related to the medical image on a data processing device. Also, the method may include storing the medical image and the description data related to the medical image in a data storage device.
Disclosed are compositions inducing cleavage of an RNA substrate, as well as their use for inducing cleavage of RNA substrates in vitro and in vivo. The compositions contain part of an active center, with the other part of the active center provided by the RNA substrate. The subunits of the active center region of the compositions are nucleotides and/or nucleotide analogues. The disclosed compositions also have flanking regions contributing to the formation of a specific hybridization with an RNA substrate. Preferred compositions form, in combination with an RNA substrate, a structure resembling a hammerhead structure. The active center of the disclosed compositions is characterized by the presence of I 15.1  which allows cleavage of RNA substrates having C 16.1 .
Right ventricular infarction (RVI) complicates 50% of cases of acute inferior ST-segment elevation myocardial infarction, and is associated with high in-hospital morbidity and mortality. Ischemic right ventricular (RV) systolic dysfunction decreases left ventricular preload delivery, resulting in low-output hypotension with clear lungs, and disproportionate right heart failure. RV systolic performance is generated by left ventricular contractile contributions mediated by the septum. Augmented right atrial contraction optimizes RV performance, whereas very proximal occlusions induce right atrial ischemia exacerbating hemodynamic compromise. RVI is associated with vagal mediated bradyarrhythmias, both during acute occlusion and abruptly with reperfusion. The ischemic dilated RV is also prone to malignant ventricular arrhythmias. Nevertheless, RV is remarkably resistant to infarction. Reperfusion facilitates RV recovery, even after prolonged occlusion and in patients with severe shock. However, in some cases hemodynamic compromise persists, necessitating pharmacological and mechanical circulatory support with dedicated RV assist devices as a "bridge to recovery."
The prevalence of depression significantly increases during puberty and adolescence. Puberty is the period during which sexual maturity is attained, while adolescence persists beyond puberty and includes physiological, social, emotional, and cognitive maturation. A stressor that has been shown previously to induce depression is chronic sleep disruption. Probiotics can prevent stress-induced depression. However, it was unclear whether probiotics could prevent depression following chronic sleep disruption and what mechanism may be involved. Therefore, we investigated whether pubertal probiotic treatment could prevent depression-like behavior in mice following chronic sleep disruption. We also examined whether probiotic treatment could improve sleep quality, and increase serotonin, tryptophan, glucose, and L-lactate concentrations in chronically sleep-disrupted mice. We hypothesized that probiotic treatment would prevent depression-like behavior, improve sleep quality, and increase serotonin, tryptophan, glucose, and L-lactate concentrations in sleep-disrupted mice. Male and female mice (N=120) received cannula and electroencephalogram (EEG) electrode implants at postnatal day (PND) 26. Mice received Lacidofil® or Cerebiome® probiotics (PND 33-51) and were sleep-disrupted for the first 4 hours of the light phase (sleep period) (PND 40-51). Hippocampal L-lactate and glucose concentrations and sleep were measured over a 24-h period (PND 48-49). Depression-like behaviour was evaluated using tail suspension (PND 49) and forced swim tests (PND 50). Chronic sleep disruption increased depression-like behaviour and NREM duration in the dark phase, and reduced all metabolites and neuromodulating biomolecules measured within the brain. However, mice treated with probiotics did not display depression-like behaviour or decreased hippocampal L-lactate following chronic sleep disruption. Cerebiome prevented decreases to prefrontal serotonin and hippocampal glucose concentrations, while Lacidofil increased NREM duration in the latter half of the light phase. The current study not only replicates previous findings linking chronic sleep disruption to depression, but also demonstrates that pubertal probiotic treatment can mitigate the effects of chronic sleep disruption on depression-like behaviour and on the neural mechanisms underlying depression in a strain-dependent manner.
The various embodiments herein provide a hyper branched polyester and a method of synthesizing the same. The embodiments herein also provide a method of encapsulating a drug into the void spaces of the polymer to act as a drug delivery system. The hyper branched polyester mer comprises an acidic moiety and an alcoholic moiety. The acidic moiety is citric acid monohydrate. The alcoholic moiety is glycerol. The acidic moiety and the alcoholic moiety are randomly arranged in the hyperbranched polymer. The method comprises of heating the mixture of citric acid and glycerol at temperatures of 90 to 150° C. by constant stirring for different time periods. In the method of encapsulation, the drug solution is drop-wise added to polymer solution at 37° C. by constant stirring for 24 h.